Item 7.01. Regulation FD Disclosure.
On May 4, 2022, Compass Therapeutics, Inc. (the “Company”) issued a press
release announcing positive interim data for its ongoing Phase 2 clinical trial
assessing its clinical program, CTX-009, in combination with paclitaxel in
advanced biliary tract cancers. A copy of the press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Also on May 4, 2022, the Company hosted a conference call to discuss the
foregoing interim Phase 2 data. A copy of the slide presentation used during the
Company’s conference call is attached hereto as Exhibit 99.2 and is incorporated
herein by reference.
The information in this Item 7.01 (including Exhibit 99.1 and Exhibit 99.2)
shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Press Release issued on May 4, 2022 titled "Compass
99.1 Therapeutics Reports Positive Interim Phase 2 Data of CTX-009
in Combination with Paclitaxel in Biliary Tract Cancers"
99.2 Presentation titled "Compass Therapeutics Program Update -
May 4, 2022"
104 Cover Page Interactive Data File (embedded within the Inline
XBRL document)
© Edgar Online, source Glimpses
postbrexitcompliance.com 